Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Documenti analoghi

• Erratum for Rhee et al., “Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants”
  di: Rhee, Elizabeth G., et al.
  Pubblicazione: (2018)
• Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin
  di: Bhagunde, Pratik, et al.
  Pubblicazione: (2020)
• Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
  di: Rizk, Matthew L., et al.
  Pubblicazione: (2018)
• Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
  di: Bhagunde, Pratik, et al.
  Pubblicazione: (2019)
• Pharmacokinetics of imipenem-cilastatin in neonates.
  di: Freij, B J, et al.
  Pubblicazione: (1985)